A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples